Our results, therefore, suggest that NLRP3-inflammasome-related miRNAs and their regulated cytokines or receptors could represent a novel diagnostic or therapeutic target in pulmonary sequelae of COVID-19-related ARDS. Here, NLRP3 is linked to COVID-19.